98%
921
2 minutes
20
Objectives: In-house developed liquid-chromatography mass spectrometry (LC-MS/MS) methods are used more and more frequently for the simultaneous quantification of vitamin D metabolites. Among these, 24,25-dihydroxyvitamin D3 (24,25(OH)D) is of clinical interest. This study assessed the agreement of this metabolite in two validated in-house LC-MS/MS methods.
Methods: 24,25(OH)D was measured in 20 samples from the vitamin D external quality assurance (DEQAS) program and in a mixed cohort of hospital patients samples (n=195) with the LC-MS/MS method at the Medical University of Graz (LC-MS/MS 1) and at the University of Liège (LC-MS/MS 2).
Results: In DEQAS samples, 24,25(OH)D results with LC-MS/MS 1 had a proportional bias of 1.0% and a negative systemic difference of -0.05%. LC-MS/MS 2 also showed a proportional bias of 1.0% and the negative systemic bias was -0.22%. Comparing the EQA samples with both methods, no systemic bias was found (0.0%) and the slope was 1%. The mean difference of 195 serum sample measurements between the two LC-MS/MS methods was minimal (-0.2%). Both LC-MS/MS methods showed a constant bias of 0.31 nmol/L and a positive proportional bias of 0.90%, respectively.
Conclusions: This study is the first to assess the comparability of 24,25(OH)D concentrations in a mixed cohort of hospitalized patients with two fully validated in-house LC-MS/MS methods. Despite different sample preparation, chromatographic separation and ionization, both methods showed high precision measurements of 24,25(OH)D. Furthermore, we demonstrate the improvement of accuracy and precision measurements of 24,25(OH)D in serum samples and in the DEQAS program.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1515/cclm-2021-0792 | DOI Listing |
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDFACS Omega
September 2025
Global Drug Metabolism and Pharmacokinetics, Eisai Co., Ltd.Tokodai 5-1-3, Tsukuba, Ibaraki 300-2635, Japan.
Irsenontrine is a novel phosphodiesterase-9 inhibitor that has been developed for the treatment of cognitive dysfunction. To assess the pharmacokinetics, excretion, and distribution of the drug in humans, comprehensive assays for irsenontrine were developed using liquid chromatography with tandem mass spectrometry (LC-MS/MS) in three human matrices, including plasma, urine, and cerebrospinal fluid (CSF). Irsenontrine was extracted from the matrices by a straightforward protein precipitation method and subsequently separated on a reverse-phase column.
View Article and Find Full Text PDFFood Sci Nutr
September 2025
Chemistry Laboratory, Kouba Higher Normal School, Algiers Kouba Algeria.
The objective of this investigation was to assess the biological properties of the leaf's aqueous extract of (PaAE), which is used in conventional medicine for therapeutic purposes of gastric ulcers and abdominal diseases. The content of phenolic and flavonoidic compounds was quantitatively estimated using colorimetric methods. The phenolic component profile was also evaluated using LC-MS/MS.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Pediatric Nephrology, Radboud University Medical Centre, Amalia Children's Hospital, Nijmegen, Netherlands.
Hemolytic uremic syndrome caused by an invasive infection (SP-HUS) is a rare and severe disease that primarily affects children under two years of age. The pathophysiology of SP-HUS remains poorly understood, and treatment is largely supportive. Complement factor H (FH) is a key regulator of the alternative pathway of the complement system.
View Article and Find Full Text PDFNeuro Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Disruption of the blood-brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs.
Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning.